NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Enrolling By InvitationN/A

Sponsor: Johns Hopkins University

Conditions: Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity

Interventions: Ofatumumab

Countries: United States

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Between 18 - 70 years of age
2. Have RMS as confirmed by the treating neurologist based on the 2017 revised McDonald criteria

   AND Either
   * be due to commence ofatumumab within 60 days of baseline OCT/VA/phlebotomy or
   * be existing patients attending the center and already receiving ofatumumab, be eligible for inclusion, and already undergoing all of the proposed study procedures.
3. Willing to sign informed consent
4. Willing to undergo phlebotomy

Exclusion Criteria:

* Uncontrolled Diabetes
* Uncontrolled Hypertension
* Glaucoma
* Refractive errors of +/- 6 diopters
* Other neurologic or ophthalmologic disorders

Locations (1)

Baltimore, Maryland, United States